New venue and keynote speaker!

To mark the return from the summer break, Espace MicroCaps is excited to organize a special event in September!

For the occasion, our 5to7 Cocktail – Healthcare Special will move to the mezzanine of the 1909 Taverne Moderne restaurant, which is adjacent to the Bell Center and close to our traditional venue (Bier Markt). The atmosphere will be relaxed and friendly! This special event will take place on September 11^th, from 5pm to 7pm.

We are also proud to announce the participation of an eminent guest speaker: Brian Bloom, CEO and co-founder of Bloom Burton & Co, one of Canada’s leading healthcare investment banks. In his keynote speech, Mr. Bloom will share his investment philosophy, advice about how to invest profitably in the healthcare sector, and which trends investors should look out for.

Following the keynote speech, we will have the privilege of hearing from three industry leaders: Crescita Therapeutics (TSX: CTX), Medexus Pharmaceuticals (TSX Venture: MDP) and Appili Therapeutics (TSX Venture: APLI). The three companies have been selected based on the quality of their fundamentals and long-term potential.

 

*New Venue* 1909 Taverne Moderne mezzanine, 1280 Canadiens-de-Montreal Avenue, Montreal

When: Wednesday, September 11^th from 5:00pm to 7:00pm

Cost: 5$ / All of the ticket sales proceeds will be given to charity.

Format: Networking period until 5:30pm, followed by a keynote speech and three company presentations. You are welcome to stay for more networking after the presentations at 7:00pm.

The first 75 participants to register and attend the event by 5:30 pm will receive a complimentary drink of their choice from a selection of 40 draft beers, wines, cocktails and spirits. Small bites and appetizers will be served during the cocktail.

To reserve your spot: Eventbrite – Espace MicroCaps 5to7 Cocktail – Healthcare Special

 

Keynote Speaker: Brian Bloom, CEO and Co-Founder of Bloom Burton & Co.

About Brian Bloom: Brian Bloom is a co-founder of Bloom Burton & Co. and serves as the firm’s Chairman and Chief Executive Officer. By forging unique relationships with international healthcare-specialized investors, Brian raises capital for Canadian healthcare companies while helping investors realize returns.

Brian serves as the Chairman of the Board of Triumvira Immunologics, and serves on the Board of Directors of Appili Therapeutics, Satellos Bioscience and Qing Bile Therapeutics. Brian is also on the Faculty of Science Dean’s Advisory Board at McMaster University. Brian was formerly the Chairman of the Board of Grey Wolf Animal Health, a member of the Life Sciences Advisory Board at the National Research Council of Canada and on the Boards of BIOTECanada and the Baycrest Foundation.

Before co-founding Bloom Burton in 2008, Brian spent six years at Dundee Securities in the healthcare and biotechnology institutional sales and equity research groups. Brian started his career at New York-based investment banking firms SCO Financial Group and Molecular Securities. Brian received an Honors Bachelor of Science in Biochemistry from McMaster University and subsequently studied at the Mount Sinai Graduate School for Biological Sciences of New York University, with a focus in molecular endocrinology and biophysics. Brian is the proud recipient of the McMaster University 2017 Distinguished Alumni Award in Science.

About Bloom Burton & Co.: Bloom Burton & Co. is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deep level of diligence, which combined with its creative and entrepreneurial approach, assists its clients in achieving the right monetization events. Bloom Burton and its affiliates provide capital raising, M&A advisory, equity research, business strategy and scientific consulting, advisory on direct investing and company creation and incubation services.

 

Crescita Therapeutics (TSX: CTX)

About: Crescita is a Canadian commercial dermatology company with manufacturing capabilities and a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions and diseases and their symptoms. Crescita owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active drugs into or through the skin.

Opportunity: Since the arrival of a new CEO in April 2018 and the implementation of a new strategy, Crescita has undergone an impressive transformation. From an operating loss of $6.2 million in 2017 to breakeven in 2018, to an operating profit of $5.1 million for the first six months of 2019, the company is on a spectacular growth trajectory. With management’s outstanding execution so far, we bet that Crescita will surprise many people in the years to come.

 

Medexus Pharmaceuticals (TSX Venture: MDP)

About: Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through its core values of Quality, Innovation, Customer Service and Teamwork. Medexus is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.

Opportunity: Medexus was born from the merger of three companies, Pediapharm, Medac Pharma and Medexus, in October 2018. Medexus emerged from this major transaction with a diversified portfolio of fast-growing commercial products that are commercialized by a direct sales force. With over $29 million in cash, the company is now seeking to acquire rights to new products that can be sold through its existing commercial infrastructure. The announcements of acquisitions or license agreements could prove to be important catalysts for Medexus in the coming months.

 

Appili Therapeutics (TSX Venture: APLI)

About: Appili was founded to advance the global fight against infectious disease by matching clearly-defined patient needs with drug development programs that provide solutions to existing challenges patients, doctors, and society face in this challenging disease space. Appili has built a pipeline of assets designed to address a broad range of significant unmet medical needs in the infectious disease landscape. This diverse pipeline aims to address some of the most urgent threats in global public health. Headquartered in Halifax, Nova Scotia, with offices in Mississauga, Ontario, Appili is pursuing worldwide opportunities in collaboration with science and industry commercial partners, governments and government agencies.

Opportunity: Appili recently went public, on June 25^th, 2019. The current market capitalization of the company, which is under $15 million, seems like a bargain compared to the $34 million that was invested since the company was founded four years ago. Appili is well capitalized, with a comfortable cash position to fund its development programs, and enjoys the support of a major strategic shareholder (Bloom Burton & Co.). Its portfolio of three very promising programs could offer several important catalysts in the coming months!

 

You won’t want to miss this exceptional event! Join us to learn more about investing in the healthcare sector, to hear about three new opportunities and to meet many other microcap enthusiasts.

Again, to book a ticket, please click here.

We hope to see many of you on September 11^th!

Philippe and Mathieu 

 

Disclosure

Espace MicroCaps is under contract with Rivemont Investments (“Rivemont”) to provide securities and strategy analysis for the Rivemont MicroCap Fund (the “Fund”). In other words, Espace MicroCaps acts as external expert/consultant for the Fund. In return for this expertise, Espace MicroCaps is remunerated by Rivemont.

Decisions as to whether or not to trade a security for the Fund are made exclusively by Rivemont.

For full disclosure and transparency, regarding the companies that will present at our 5to7 Cocktail – Healthcare Special or that were mentioned in this article, the Fund:

• Holds securities of Crescita Therapeutics (CTX.TO) and Medexus Pharmaceuticals (MDP.V).
• Does not hold any securities of Appili Therapeutics (APLI.V).

This information is valid as of the date of publication of this article. The Fund may acquire more or dispose of these securities in the future.

The main objective of the 5to7 Cocktail events that we hold on a regular basis is to allow very small companies to present their products and services and to tell their story to a new investing public.

Each company that will present at the event will pay Espace MicroCaps an amount of $2,000 + taxes. This amount is used to cover the cost of drinks and hors d’oeuvres offered during the event and to compensate Espace MicroCaps for the efforts related to the organization of the event.

Company presentations are neither an offer to sell nor a solicitation of an offer to purchase securities and should not be considered legal, tax, financial or investment advice.

Espace MicroCaps is not responsible for direct or indirect trading losses caused by the information presented by companies at the event. Everyone is advised to make their own analyses and inquiries and to consult their own professional advisers with respect to legal, tax, accounting and other matters relating to the acquisition, holding or disposition of an investment.